Taken together, these results show that UCP1-CRISPRa-modulated human adipose organoids significantly reduce glycolysis and FAO, reduce hypoxia and inhibit tumor growth for four different cancer types in vivo. The gene discussed is UCP1; the disease is neoplasm.